Herceptin/Biosimilars, Trastuzumab-Hyaluronidase (coverage criteria)
Customize your policy alerts
Sign up for Arizona Complete Health Policy AZ.CP.PHAR.228 alerts
Get alerted when Policy AZ.CP.PHAR.228 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and prior authorization criteria for trastuzumab, its biosimilars, and trastuzumab-hyaluronidase (Herceptin Hylecta) for Arizona Complete Health Medicaid lines of business (AzCH-CCP and Care1st). Applies to providers prescribing these agents for oncology indications.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.